Go to main content
Type 2

Remarkable Weight Loss With Once Daily Semaglutide Pill

Early findings from a phase 3 clinical trial demonstrated that participants treated with 50 mg oral semaglutide achieved a remarkable weight loss of 17.4%. This research could lead to a once-daily pill alternative to popular weight loss injections such as Ozempic and Wegovy.

Novo Nordisk shared encouraging results from OASIS 1, a phase 3 clinical trial for the once-daily oral semaglutide 50 mg for weight management in 667 adults dealing with obesity. 

The groups in the trial received either oral semaglutide or a placebo in combination with lifestyle intervention. The trial results showed superior weight loss after 68-weeks among those taking the drug compared to the placebo.

“The results show comparable weight loss as in the STEP 1 trial with injectable semaglutide 2.4 mg in obesity branded as Wegovy,” Martin Holst Lange, executive vice president of development at Novo Nordisk, said in a statement. 

From an average weight of 232.4 pounds, or 105.4 kg, individuals treated with 50 mg of oral semaglutide lost 17.4% on average of their body weight after 68 weeks, in contrast to a 1.8% reduction observed in the placebo group. Additionally, nearly 90% of the participants achieved a weight loss of at least 5%, compared to only 24.5% in the placebo group. 

These findings are consistent with the PIONEER PLUS trial, which investigated the weight loss from high dose oral semaglutide for people with type 2 diabetes.

Oral semaglutide, available at 3 mg, 7 mg, and 14 mg doses and sold as Rybelsus, is currently used to treat type 2 diabetes. Wegovy, an injectable form of the same medication, is also approved for weight loss. If this high dose oral semaglutide eventually receives FDA approval, it could provide a choice between a daily tablet or a weekly injection, providing people with obesity and their healthcare providers options that best suit individual preferences.

To learn more about semaglutide and weight loss, read our other articles: